BIOTECH
This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was...
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up...
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines...
The transaction reflects a pre-money equity value of $400 million for AUM Biosciences Transaction is...
Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders...